JP6796594B2 - 造影剤およびその用途 - Google Patents

造影剤およびその用途 Download PDF

Info

Publication number
JP6796594B2
JP6796594B2 JP2017549559A JP2017549559A JP6796594B2 JP 6796594 B2 JP6796594 B2 JP 6796594B2 JP 2017549559 A JP2017549559 A JP 2017549559A JP 2017549559 A JP2017549559 A JP 2017549559A JP 6796594 B2 JP6796594 B2 JP 6796594B2
Authority
JP
Japan
Prior art keywords
contrast agent
contrast
mmol
alkyl
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502150A (ja
JP2018502150A5 (enExample
Inventor
ジードン チャン，
ジードン チャン，
ケン カリー，
ケン カリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RF Therapeutics Inc
Original Assignee
RF Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RF Therapeutics Inc filed Critical RF Therapeutics Inc
Publication of JP2018502150A publication Critical patent/JP2018502150A/ja
Publication of JP2018502150A5 publication Critical patent/JP2018502150A5/ja
Application granted granted Critical
Publication of JP6796594B2 publication Critical patent/JP6796594B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2017549559A 2014-12-11 2015-12-10 造影剤およびその用途 Active JP6796594B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462090519P 2014-12-11 2014-12-11
US62/090,519 2014-12-11
US201562189414P 2015-07-07 2015-07-07
US62/189,414 2015-07-07
PCT/CA2015/051304 WO2016090491A1 (en) 2014-12-11 2015-12-10 Targeted contrast agents comprising a hydrazide functional group

Publications (3)

Publication Number Publication Date
JP2018502150A JP2018502150A (ja) 2018-01-25
JP2018502150A5 JP2018502150A5 (enExample) 2019-01-24
JP6796594B2 true JP6796594B2 (ja) 2020-12-09

Family

ID=56106370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549559A Active JP6796594B2 (ja) 2014-12-11 2015-12-10 造影剤およびその用途

Country Status (6)

Country Link
US (1) US10286090B2 (enExample)
EP (1) EP3229848B1 (enExample)
JP (1) JP6796594B2 (enExample)
CN (1) CN106999610A (enExample)
CA (1) CA2968261C (enExample)
WO (1) WO2016090491A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101864992B1 (ko) * 2017-03-09 2018-07-04 국립암센터 Mri 노이즈 제거용 조성물 및 이를 이용한 패드
CN107353258B (zh) * 2017-06-19 2019-09-24 南京科技职业学院 两种二核含钆磁共振成像对比剂及其制备与应用
CN110511176A (zh) * 2019-09-12 2019-11-29 陕西科技大学 双(2-邻苯二甲酰亚胺)胺及其制备方法
CN111606838B (zh) * 2020-06-19 2023-06-30 宁夏大学 一种双吲哚基甲烷类化合物的制备方法
CN111825703B (zh) * 2020-08-04 2023-06-23 江西司太立制药有限公司 一种钆贝葡胺注射液杂质的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3621018A (en) 1968-06-28 1971-11-16 Hooker Chemical Corp 2,6-diketo-n-carboxymethylmorpholine
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
DE19744003B4 (de) * 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6146615A (en) 1999-01-11 2000-11-14 The University Of Toledo Contrast agents for image enhancement in magnetic resonance imaging
US6641797B2 (en) 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
GB2368843A (en) 2000-11-08 2002-05-15 Leuven K U Res & Dev Non-porphyrin multipurpose contrast agents
AU2002218075A1 (en) 2000-11-08 2002-05-21 K.U. Leuven Research And Development Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
DE10105014C2 (de) 2001-01-26 2003-03-27 Schering Ag Neues Verfahren zur Herstellung von Monoamiden der DTPA
ATE411819T1 (de) * 2003-02-17 2008-11-15 Upperton Ltd Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
GB0317467D0 (en) 2003-07-25 2003-08-27 Leuven K U Res & Dev Tissue infraction and necrosis specific compounds
WO2008088648A2 (en) * 2007-01-11 2008-07-24 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
EP2651411B1 (en) 2010-12-13 2020-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
CN103547290A (zh) * 2011-04-20 2014-01-29 Rf医疗公司 靶向造影剂及其用途

Also Published As

Publication number Publication date
JP2018502150A (ja) 2018-01-25
CA2968261A1 (en) 2016-06-16
EP3229848A4 (en) 2018-07-18
EP3229848A1 (en) 2017-10-18
CN106999610A (zh) 2017-08-01
EP3229848B1 (en) 2020-08-12
US10286090B2 (en) 2019-05-14
WO2016090491A1 (en) 2016-06-16
US20170340757A1 (en) 2017-11-30
CA2968261C (en) 2021-08-17

Similar Documents

Publication Publication Date Title
US20140065075A1 (en) Targeted contrast agents and uses thereof
JP6796594B2 (ja) 造影剤およびその用途
JP6896733B2 (ja) 二量体造影剤
BRPI0617151B1 (pt) Composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico
CA3002512A1 (en) Macrocyclic chelating ligand and use thereof as contrast agent
JP7145156B2 (ja) 二量体造影剤
JP6087386B2 (ja) 造影剤としてのｎ−アルコキシアミド抱合体
JP6826989B2 (ja) エチレンジアミン四酢酸ビス（アミド）誘導体およびＭＲＩ造影剤としての使用のためのそれらのＭｎ（ＩＩ）イオンとの錯体
WO2022241470A1 (en) Molecular probes for in vivo detection of aldehydes
BR112017026135B1 (pt) Compostos de quelato de gadolínio, seus intermediários, seus usos e seu método de preparação, e método para geração de imagem de tecido corporal em um paciente

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20181025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201116

R150 Certificate of patent or registration of utility model

Ref document number: 6796594

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250